Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Phase
Phase 1
Started
2026-08-20
Last updated
2026-08-27
Condition(s) studied
Healthy
Investigational drug(s) / intervention(s)
HW243040Placebo
HW243040: HW243040 will be administered orally as a tablet.
Placebo: Placebo will be administered orally as a tablet.
Study summary
This is a randomised, double-blind, placebo-controlled clinical trial intended to evaluate the safety, tolerability and pharmacokinetic profiles of HW243040 following single and multiple administrations in healthy study participants.
Eligibility
Sex
ALL
Min age
18 Years
Max age
55 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Informed consent must be obtained/signed prior to trial participation.
* Aged between 18 and 55 years old, both healthy males and females are eligible.
* Female participates must have a body weight of ≥ 45 kg and male participates ≥ 50 kg, with a body mass index (BMI) ranging from 19 to 26 kg/m\^2.
Exclusion Criteria:
* History or presence of any clinically severe disorders of urinary, cardiovascular, endocrine, nervous, gastrointestinal, respiratory, hematologic, immune systems, psychiatric illnesses or metabolic abnormalities; or other conditions judged by the Investigator to confound trial outcomes, e.g., intestinal diseases (irritable bowel syndrome), urinary tract infections.
* History of malignant tumors (except for cancer with confirmed cure or remission for ≥5 years, radically resected basal or squamous cell skin cancer, carcinoma in situ of the cervix, and resected colonic polyps).
* Any conditions or diseases that, in the Investigator's judgment, may affect the absorption, metabolism and/or excretion of the investigational product.
* History of drug abuse or dependence.
* Hypersensitivity to any ingredient of the study drug,or history of allergic disorders or allergic diathesis.
* Any other condition that, in the opinion of the investigator, renders the participant unsuitable to participate in the study.
Primary outcome measure(s)
The incidence and severity of adverse events — Up to day 11
Trial sites (1)
Facility
City
Region
Status
The Third Xiangya Hospital of Central South University
Changsha
Hunan
Recruiting
More Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.